SCHEMBL1371349

SCHEMBL1371349

CC(C#N)C1CCCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8522382 0.97 SHBG (0.39)
Methylamine SCHEMBL27951566 0.95 EPHX1 (0.32)
SCHEMBL937062 0.94
SCHEMBL882385 0.88
Phosphoric Acid SCHEMBL15389186 0.87 MMP2 (0.42)
Sulfuric Acid SCHEMBL15389382 0.87 EPHX1 (0.34)
Bromide SCHEMBL29487599 0.86
SCHEMBL28773707 0.80 JAK2 (0.32)
SCHEMBL2759860 0.79 TSHR (0.32)
SCHEMBL18126126 0.77 PIK3CD (0.33)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117285699-A Solid electrolyte prepolymerization liquid, solid electrolyte and electrochemical device 深圳市贝特瑞新能源技术研究院有限公司 2023-12-26 CN claimed
US-12622908-B2 Topical formulation for a JAK inhibitor INCYTE CORPORATION (US) 2026-05-12 US disclosed
US-12564593-B2 Topical formulation for a JAK inhibitor INCYTE CORPORATION (US) 2026-03-03 US disclosed
US-12544381-B2 Topical formulation for JAK inhibitor INCYTE CORPORATION (US) 2026-02-10 US disclosed
US-20250345337-A1 TOPICAL FORMULATION FOR A JAK INHIBITOR INCYTE CORP (US) 2025-11-13 US disclosed
US-20250283174-A1 METHODS FOR ASSESSING THE EXHAUSTION OF HEMATOPOIETIC STEM CELLS INDUCED BY CHRONIC INFLAMMATION UNIVERSITÉ PARIS CITÉ (FR) 2025-09-11 US disclosed
US-20250255872-A1 TOPICAL FORMULATION FOR JAK INHIBITOR INCYTE CORPORATION 2025-08-14 US disclosed
CN-120142527-A Detection method of lactetinib phosphate positional isomer 重庆药友制药有限责任公司 2025-06-13 CN disclosed
CN-119977970-A Luxolitic preparation method of nylon 雅本(绍兴)药业有限公司 2025-05-13 CN disclosed
EP-4526469-A1 METHODS FOR ASSESSING THE EXHAUSTION OF HEMATOPOIETIC STEMS CELLS INDUCED BY CHRONIC INFLAMMATION Institut National de la Santé et de la Recherche Médicale (FR) 2025-03-26 EP disclosed
EP-2486041-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE Incyte Corporation (US) 2012-08-15 EP disclosed
EP-2470534-A1 JAK INHIBITION BLOCKS RNA INTERFERENCE ASSOCIATED TOXICITIES Merck Sharp & Dohme Corp. (US) 2012-07-04 EP disclosed
US-20120157500-A1 JAK INHIBITION BLOCKS RNA INTERFERENCE ASSOCIATED TOXICITIES MERCK SHARP & DOHME CORP. 2012-06-21 US disclosed
US-20110288107-A1 TOPICAL FORMULATION FOR A JAK INHIBITOR INCYTE CORPORATION 2011-11-24 US disclosed
US-20110086810-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-d] PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 US disclosed
WO-2011044481-A1 HYDROXYL, KETO, AND GLUCURONIDE DERIVATIVES OF 3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE INCYTE CORPORATION (US) 2011-04-14 WO disclosed
WO-2011025685-A1 JAK INHIBITION BLOCKS RNA INTERFERENCE ASSOCIATED TOXICITIES MERCK SHARP & DOHME CORP. (US) 2011-03-03 WO disclosed
EP-2220068-A1 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS Incyte Corporation (US) 2010-08-25 EP disclosed
WO-2010039939-A1 JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES INCYTE CORPORATION (US) 2010-04-08 WO disclosed
WO-2009064835-A1 4-PYRAZOLYL-N-ARYLPYRIMIDIN-2-AMINES AND 4-PYRAZOLYL-N-HETEROARYLPYRIMIDIN-2-AMINES AS JANUS KINASE INHIBITORS INCYTE CORPORATION (US) 2009-05-22 WO disclosed